open access

Vol 16, No 1 (2020)
Review paper
Published online: 2020-02-28
Get Citation

The evolution of biologics in the context of oncological therapy

Bartłomiej Żerek, Wojciech Straś, Piotr Rózga, Elżbieta Pękala
DOI: 10.5603/OCP.2020.0001
·
Oncol Clin Pract 2020;16(1):14-21.

open access

Vol 16, No 1 (2020)
REVIEW ARTICLES
Published online: 2020-02-28

Abstract

Progress in the field of pharmacy, closely related with the mutual stimulation of natural sciences and new technologies available to researchers, has been so rapid over the last few decades that it has begun to cause problems at the level of definitions and classifications. This phenomenon refers also to the term of biologics or, more widely, to biopharmaceuticals (in Polish terminology). The first associations with the above terms lead our thoughts to recombinant proteins, such as insulin used in the treatment of diabetes or monoclonal antibodies with wide, in terms of therapeutic areas, applications. It is generally believed that the above category of drugs is not associated with preparations invented long before the discovery of nucleic acids, let alone before the invention of an ordinary bulb. Importantly, the connotation of the term biopharmaceuticals is undergoing a very rapid reconstruction before our eyes, and the set of referents is expanding with newer, previously unknown types of therapies. Technological progress is one of the driving forces of these changes. Unmet medical needs, including the ones in the area of oncology, constitute another driving force.

Abstract

Progress in the field of pharmacy, closely related with the mutual stimulation of natural sciences and new technologies available to researchers, has been so rapid over the last few decades that it has begun to cause problems at the level of definitions and classifications. This phenomenon refers also to the term of biologics or, more widely, to biopharmaceuticals (in Polish terminology). The first associations with the above terms lead our thoughts to recombinant proteins, such as insulin used in the treatment of diabetes or monoclonal antibodies with wide, in terms of therapeutic areas, applications. It is generally believed that the above category of drugs is not associated with preparations invented long before the discovery of nucleic acids, let alone before the invention of an ordinary bulb. Importantly, the connotation of the term biopharmaceuticals is undergoing a very rapid reconstruction before our eyes, and the set of referents is expanding with newer, previously unknown types of therapies. Technological progress is one of the driving forces of these changes. Unmet medical needs, including the ones in the area of oncology, constitute another driving force.

Get Citation

Keywords

biologics, biopharmaceuticals, recombinant proteins, monoclonal antibodies, CAR-T, gene therapy

About this article
Title

The evolution of biologics in the context of oncological therapy

Journal

Oncology in Clinical Practice

Issue

Vol 16, No 1 (2020)

Article type

Review paper

Pages

14-21

Published online

2020-02-28

DOI

10.5603/OCP.2020.0001

Bibliographic record

Oncol Clin Pract 2020;16(1):14-21.

Keywords

biologics
biopharmaceuticals
recombinant proteins
monoclonal antibodies
CAR-T
gene therapy

Authors

Bartłomiej Żerek
Wojciech Straś
Piotr Rózga
Elżbieta Pękala

References (26)
  1. Baxby D. Edward Jenner's Inquiry; a bicentenary analysis. Vaccine. 1999; 17(4): 301–307.
  2. Jesty R. Who invented vaccination? Malta Medical Journal. 2011; 23(02): 29–32.
  3. Jakubiak M. Historia pędzlaka, czyli początek antybiotyków. Gazeta Lekarska. 2014; 11(12): 16–18.
  4. Quinn R. Rethinking antibiotic research and development: World War II and the penicillin collaborative. Am J Public Health. 2013; 103(3): 426–434.
  5. Bose B, Katikireddy KR, Shenoy PS. Regenerative medicine for diabetes: differentiation of human pluripotent stem cells into functional β-cells in vitro and their proposed journey to clinical translation. Vitam Horm. 2014; 95: 223–248.
  6. Rosenfeld L. Insulin: discovery and controversy. Clin Chem. 2002; 48(12): 2270–2288.
  7. Jarecka M, Borowicz P. Terapeutyczne i rynkowe perspektywy rekombinowanych leków. Biotechnologia. 2005; 4(71): 7–27.
  8. Global Pharmaceutical Biotech Market 2010–2025. Visiongain. 2009.
  9. Global & USA Biosimilar Market Analysis to 2021. KellySciPub. 2015.
  10. Perspectives of the evolving biosimilars landscape. IMS Health. 2015.
  11. The Therapeutic Proteins Outlook to 2007: An Analysis of Leading Products and Late-Stage Pipeline Developments. Research and Markets. 2003.
  12. Dutcher JP. Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma. Oncology (Williston Park). 2002; 16(11 Suppl 13): 4–10.
  13. Kaminetzky D, Hymes KB. Denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Biologics. 2008; 2(4): 717–724.
  14. Dotan E, Aggarwal C, Smith MR. Impact of rituximab (Rituxan) on the treatment of beta-cell non-Hodgkin's lymphoma. Pharmacy and Therapeutics. 2010; 35(3): 148–157.
  15. Robak T. Alemtuzumab for B-cell chronic lymphocytic leukemia. Expert Review of Anticancer Therapy. 2014; 8(7): 1033–1051.
  16. Liu H, Saxena A, Sidhu SS, et al. Fc engineering for developing therapeutic bispecific antibodies and novel scaffolds. Front Immunol. 2017; 8(38): 1–15.
  17. Topp MS, Gökbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015; 16(1): 57–66.
  18. Gravanis I, Tzogani K, van Hennik P, et al. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use. Oncologist. 2016; 21(1): 102–109.
  19. Albanell J. Mechanisms of action of the HER dimerization inhibitor pertuzumab alone or with trastuzumab”. Cancer and Chemotherapy Reviews. 2013; 8(1): 24–32.
  20. Braghiroli MI, Sabbaga J, Hoff PM. Bevacizumab: overview of the literature. Expert Rev Anticancer Ther. 2012; 12(5): 567–580.
  21. Stanel SC, Sjöberg J, Salmonson T, et al. European Medicines Agency approval summary: Zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancer. ESMO Open. 2017; 2(2): e000190.
  22. Swatler J, Kozłowska E. Immune checkpoint‑targeted cancer immunotherapies. Postępy Hig Med. Dosw. 2016; 70: 25–42.
  23. Lipson EJ, Drake CG. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res. 2011; 17(22): 6958–6962.
  24. Fessas P, Lee H, Ikemizu S, et al. A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab. Semin Oncol. 2017; 44(2): 136–140.
  25. Brown A, Gardner J, Elmhirst E. Vantage 2019 Preview. Evaluate 2018.
  26. Top 20 Blockbuster Cancer Drugs. The Balance. 2018, https://www.thebalance.com/top-cancer-drugs-2663234.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl